AI Analysis
Summary
Bayer is acquiring Perfuse Therapeutics for $300 million upfront, with total deal value reaching $2.45 billion, to advance an eye implant for glaucoma and diabetic retinopathy. This marks Bayer's first pharmaceutical acquisition since 2021.
Outcome Details
Bayer acquiring Perfuse Therapeutics for $300 million upfront with up to $2.45 billion total consideration
Importance:7/10
Sentiment:
0.70
M&Aacquisitionophthalmologyeye implantglaucomadiabetic retinopathy
Related Companies
Read the original article
Published by BioSpace on May 6, 2026 12:45 PM